SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

Share Price is delayed by 15 minutes
Get Live Data
17.00    0.00 (0.00%)
Bid:
16.00
Ask:
18.00
Spread: 2.00 (12.50%)
Market Cap: £12.86m
FIPP Live PriceLast checked at - London Stock Exchange

Intraday Frontier Ip Share Chart

Molendotech signs collaboration agreement with G's

19 Oct 2018 07:00

RNS Number : 5198E
Frontier IP Group plc
19 October 2018
 

Frontier IP Group Plc

("Frontier IP" or the "Group")

 

 

Portfolio news - Molendotech signs collaboration agreement with leading European fresh produce company G's Group

 

Frontier IP, which specialises in commercialising university intellectual property, today announces that portfolio company Molendotech Ltd (the "Company") has entered into a collaboration agreement to develop water tests for G's Group ("G's or the "Grower"), one of Europe's leading fresh produce companies.

 

Molendotech, a University of Plymouth spin out, will work with G's to create tests to detect the levels of different bacteria in produce, irrigation, washing water and food contact areas. Work is expected to start immediately.

 

The move represents another important step in commercialising the Company's technology. The technology being developed for G's could potentially cut the time to conduct the tests from up to two days currently to less than an hour.

 

Molendotech was incorporated last year to develop and commercialise the work of Professor Simon Jackson, at the University of Plymouth faculty of Medicine and Dentistry. The Company is already working with Palintest, a subsidiary of FTSE 100 group Halma, which is launching kits based on Molendotech's IP to test for faecal matter in bathing water. Frontier IP owns 14.1 per cent of the Company

 

G's Group farms, grows, sources and packages a wide range of fresh produce and supplies many major European retailers, including Aldi, Asda, Co-op, Lidl, M&S, Sainsbury's, Tesco and Waitrose. The Grower has operations in the UK, Spain, Eastern Europe, the United States and South Africa.

 

G's Group technical innovation and chilled foods director Darren Gedge said: "This is a great opportunity for G's. We recognise that there is tremendous scope to improve turnaround time for micro testing, which will enable us to confidently release our products to our customers."

 

Molendotech director Professor Simon Jackson said: "This is an exciting opportunity for Molendotech and will allow us to develop our technology in the important food market where a rapid turn around of produce is required. We are looking forward to working with G's to develop rapid new tests for their fresh produce"

 

Frontier IP chief executive officer Neil Crabb said: "We're delighted with this further industry backing for Molendotech's unique IP. Fresh produce is one of the many sectors where we believe the Company can make a real difference."

 

ENQUIRIES

 

Frontier IP Group Plc

T: 0131 240 1251

Neil Crabb, Chief Executive

Andrew Johnson, Communications & Investor Relations

Company website: www.frontierip.co.uk

 

M: 07464 546 025

Allenby Capital Limited (Nominated Adviser and Broker)

T: 0203 328 5656

Nick Athanas / Nicholas Chambers (Corporate Finance)

Amrit Nahal (Equity Sales)

 

Molendotech Limited T: 01803 659203

Simon Jackson, CEO M: 07384 469486

 

NOTES TO EDITORS

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services.

The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAFMMMGDRNGRZM
Date   Source Headline
26th May 20267:00 amRNS-RPortfolio news: Dekiln strategic partnership
5th May 20267:00 amRNSAppointment of Chief Financial Officer
16th Apr 20264:07 pmRNSHolding(s) in Company
15th Apr 20267:00 amRNSPortfolio News: 2D Photonics subsidiary grant
13th Apr 20262:35 pmRNSHolding(s) in Company
10th Apr 202610:30 amRNSUpdate re Investee Company
8th Apr 20267:00 amRNS-RPortfolio news – Fieldwork Robotics £3M fundraise
31st Mar 20265:18 pmRNSHolding(s) in Company
30th Mar 20267:00 amRNSUnaudited Half Year Results
23rd Mar 20267:00 amRNS-RAlusid reaches milestone in European roll out
28th Jan 20264:28 pmRNSHolding(s) in Company
19th Jan 20267:00 amRNS-RPortfolio news - Strong results for TVG vaccine
12th Jan 202610:30 amRNSHolding(s) in Company
31st Dec 20251:00 pmRNSTotal Voting Rights
31st Dec 20251:00 pmRNSTotal Voting Rights
31st Dec 202512:30 pmRNSResult of AGM
31st Dec 202512:30 pmRNSResult of AGM
29th Dec 20252:37 pmRNSHolding(s) in Company
29th Dec 20252:37 pmRNSHolding(s) in Company
24th Dec 20259:52 amRNSHolding(s) in Company
24th Dec 20259:52 amRNSHolding(s) in Company
24th Dec 20257:00 amRNSHolding(s) in Company
23rd Dec 20252:17 pmRNSDirectors' Shareholdings
23rd Dec 20252:17 pmRNSDirectors’ Shareholdings
22nd Dec 20253:48 pmRNSResult of Retail Offer
22nd Dec 20253:48 pmRNSResult of Retail Offer
18th Dec 20259:15 amRNS-RDekiln benefits from £3 million funding
17th Dec 202511:54 amRNSResult of Placing and Subscription
17th Dec 20257:01 amRNSRetail Offer
17th Dec 20257:00 amRNSProposed Placing and Subscription to raise £870k
15th Dec 20257:00 amRNS-RPortfolio news- Alusid £500k pre-IPO funding round
10th Dec 20254:56 pmRNSHolding(s) in Company
9th Dec 20257:00 amRNSPosting of Annual Report & Notice of AGM
8th Dec 20257:00 amRNSFinal results for the year ended 30 June 2025
2nd Dec 20257:00 amRNS-RAlusid signs Swedish distribution agreement
6th Nov 20257:00 amRNSBord Change
3rd Nov 20257:00 amRNS-RTVG demonstrates success in animal trials
20th Oct 20257:00 amRNS-RAmprologix raises £740,000 in Pre-Series A round
25th Sep 20257:00 amRNSBoard Changes
24th Sep 20255:12 pmRNSHolding(s) in Company
13th Jun 20257:00 amRNSStrategic partnership for Cambridge innovation hub
10th Jun 20257:00 amRNS-RAlusid signs international distribution agreement
6th May 20257:00 amRNS-RTVG's vaccine candidate enters animal trials
16th Apr 20257:00 amRNS-RSyva signs option to license agreement with TVG
2nd Apr 20254:47 pmRNSDirector/PDMR Shareholding
31st Mar 20251:02 pmRNSDirector/PDMR Shareholding
26th Mar 20257:00 amRNSUnaudited Half Year Results
24th Mar 20257:00 amRNSCamGraphIC secures €25 million in Series A funding
18th Mar 20257:00 amRNS-RPulsiv wins PSMA’s Global Energy Efficiency Award
25th Feb 20257:00 amRNS-RGraphEnergyTech collaboration & Innovate UK grant

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.